Urimax

# Urimax (Tamsulosin) ## Overview - **Classification**: Alpha-1A Adrenergic Antagonist (Alpha-Blocker) - **Mechanism**: Selectively blocks alpha-1A adrenoreceptors in the prostate, bladder base, and urethra, relaxing smooth muscle and improving urinary flow. ## Primary Indications 1. **Benign Prostatic Hyperplasia (BPH)**: Management of signs and symptoms related to BPH. 2. **Kidney Stones (Off-Label)**: Facilitation of ureteral stone passage (medical expulsive therapy). ## Adult Dosing ### Standard Dosing **Benign Prostatic Hyperplasia (BPH)** - **Dose**: **0.4 mg** - **Frequency**: Once daily (QD) - **Route**: Oral - **Maximum Dose**: **0.8 mg** QD (if response is inadequate after 2-4 weeks) - **Special Consideration**: Take approximately **30 minutes after the same meal** each day. ### Dose Adjustments - **Renal Impairment**: No dosing adjustment is necessary for CrCl down to 10 mL/min. Use caution below 10 mL/min. - **Hepatic Impairment**: Not required for mild to moderate impairment. Use caution in severe hepatic impairment (not studied). - **Elderly Patients**: No specific dose reduction needed. They may be more susceptible to orthostatic hypotension. ## Pediatric Dosing Tamsulosin is **not approved** for use in pediatric patients. Safety and efficacy have not been established. ### Neonates (0-28 days) - **Dose**: Not recommended. - **Special Notes**: Use is contraindicated due to lack of safety data. ### Infants (1-12 months) - **Dose**: Not recommended. ### Children (1-12 years) - **Dose**: Not recommended. - **Maximum**: **0.4 mg** (Use only if compelling off-label need; monitor closely). ### Adolescents (13-18 years) - **Dose**: If used for off-label stone expulsion, utilize standard **adult dosing (0.4 mg QD)**. - **Maximum**: **0.8 mg** QD (use caution). ## Safety Information ### Contraindications - **Absolute**: Hypersensitivity to Tamsulosin or sulfonamides. - **Absolute**: Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole). - **Relative**: Severe orthostatic hypotension. ### Common Adverse Effects - **Very Common (>10%)**: Dizziness, Ejaculation failure/disorder (up to 18%). - **Common (1-10%)**: Headache, Rhinitis, Infection, Weakness (Asthenia), Diarrhea. - **Serious but Rare**: **Priapism** (prolonged, painful erection), Intraoperative Floppy Iris Syndrome (IFIS). ### Key Drug Interactions - **Strong CYP3A4 Inhibitors (e.g., Ketoconazole)**: Increases Tamsulosin exposure. **Avoid concomitant use.** - **Strong CYP2D6 Inhibitors (e.g., Paroxetine)**: May increase Tamsulosin exposure. Use **0.4 mg max** dose. - **Phosphodiesterase-5 Inhibitors (e.g., Sildenafil)**: Increased risk of **hypotension** and orthostasis. Use with caution. ## Monitoring & Follow-up - **Before Treatment**: Rule out prostate cancer (PSA and DRE if appropriate). Assess baseline blood pressure (BP). - **During Treatment**: Monitor BP (especially orthostatic BP) periodically. Monitor symptoms improvement using IPSS scores. - **Clinical Signs**: Watch for signs of priapism (seek immediate medical attention) or severe dizziness/fainting. ## Clinical Pearls - 💡 **Tip 1**: Tamsulosin is highly uroselective and usually causes less peripheral vasodilation and hypotension than non-selective alpha-blockers. - 💡 **Tip 2**: Advise patients to take the first dose at bedtime to mitigate dizziness/orthostasis risk. - 💡 **Tip 3**: Instruct patients planning cataract/glaucoma surgery to inform the surgeon of Tamsulosin use due to risk of **IFIS**. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.